{"id":45366,"date":"2022-06-22T17:01:25","date_gmt":"2022-06-22T15:01:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/"},"modified":"2022-06-22T17:01:25","modified_gmt":"2022-06-22T15:01:25","slug":"duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/","title":{"rendered":"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5589949\/duchenne-muscular-dystrophy-drugs-in-development?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=ckhqnr&amp;utm_campaign=1717444+-+Duchenne+Muscular+Dystrophy+Drugs+in+Development+Report+2022%3A+Featuring+FibroGenesis%2C+RegenxBio%2C+Pfizer+and+Others&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220622005703\/en\/1494036\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220622005703\/en\/1494036\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy &#8211; Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.\n<\/p>\n<p>\n<strong>Report Highlights<\/strong>\n<\/p>\n<p>\nThe Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy &#8211; Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\n<\/p>\n<p>\nThe Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected\/Withdrawn, Phase III, Phase II, Phase I, IND\/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 12, 15, 2, 71, 34 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND\/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 2, 1, 13 and 3 molecules, respectively.\n<\/p>\n<p>\nDuchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company\/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.\n<\/p>\n<p>\n<strong>Scope<\/strong>\n<\/p>\n<ul>\n<li>\nThe pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).\n<\/li>\n<li>\nThe pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities\/research institutes based on information derived from company and industry-specific sources.\n<\/li>\n<li>\nThe pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.\n<\/li>\n<li>\nThe pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&amp;D brief, MoA &amp; other developmental activities.\n<\/li>\n<li>\nThe pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.\n<\/li>\n<li>\nThe pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.\n<\/li>\n<li>\nThe pipeline guide encapsulates all the dormant and discontinued pipeline projects.\n<\/li>\n<li>\nThe pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)<\/p>\n<p>\n\u00a0\n<\/p>\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>Introduction<\/strong>\n<\/p>\n<p>\n<strong>Report Coverage<\/strong>\n<\/p>\n<p>\n<strong>Duchenne Muscular Dystrophy &#8211; Overview<\/strong>\n<\/p>\n<p>\n<strong>Duchenne Muscular Dystrophy &#8211; Therapeutics Development<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Overview\n<\/li>\n<li>\nPipeline by Companies\n<\/li>\n<li>\nPipeline by Universities\/Institutes\n<\/li>\n<li>\nProducts under Development by Companies\n<\/li>\n<li>\nProducts under Development by Universities\/Institutes\n<\/li>\n<\/ul>\n<p>\n<strong>Duchenne Muscular Dystrophy &#8211; Therapeutics Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nAssessment by Target\n<\/li>\n<li>\nAssessment by Mechanism of Action\n<\/li>\n<li>\nAssessment by Route of Administration\n<\/li>\n<li>\nAssessment by Molecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>Duchenne Muscular Dystrophy &#8211; Drug Profiles<\/strong>\n<\/p>\n<p>\n<strong>Duchenne Muscular Dystrophy &#8211; Dormant Projects<\/strong>\n<\/p>\n<p>\n<strong>Duchenne Muscular Dystrophy &#8211; Discontinued Products<\/strong>\n<\/p>\n<p>\n<strong>Duchenne Muscular Dystrophy &#8211; Product Development Milestones<\/strong>\n<\/p>\n<p>\n<strong>Featured News &amp; Press Releases<\/strong>\n<\/p>\n<p>\n<strong>Appendix<\/strong>\n<\/p>\n<p>\n<strong>Methodology<\/strong>\n<\/p>\n<p>\n<strong>Coverage<\/strong>\n<\/p>\n<p>\n<strong>Secondary Research<\/strong>\n<\/p>\n<p>\n<strong>Primary Research<\/strong>\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nAAVogen Inc\n<\/li>\n<li>\nAlpha Anomeric\n<\/li>\n<li>\nAmerican CryoStem Corp\n<\/li>\n<li>\nAnagenesis Biotechnologies SAS\n<\/li>\n<li>\nAntisense Therapeutics Ltd\n<\/li>\n<li>\nARMGO Pharma Inc\n<\/li>\n<li>\nAstria Therapeutics Inc\n<\/li>\n<li>\nAUM LifeTech Inc\n<\/li>\n<li>\nAutotac Bio Inc\n<\/li>\n<li>\nAvidity Biosciences Inc\n<\/li>\n<li>\nAxolo Pharma Inc\n<\/li>\n<li>\nBayer AG\n<\/li>\n<li>\nBiogen Inc\n<\/li>\n<li>\nBioIncept LLC\n<\/li>\n<li>\nBioleaders Corp\n<\/li>\n<li>\nBioMarin Pharmaceutical Inc\n<\/li>\n<li>\nBiophytis SA\n<\/li>\n<li>\nCANbridge Life Sciences Ltd\n<\/li>\n<li>\nCapricor Therapeutics Inc\n<\/li>\n<li>\nChengdu Fanxi Biopharma Co Ltd\n<\/li>\n<li>\nCode Biotherapeutics Inc\n<\/li>\n<li>\nConsortium.AI\n<\/li>\n<li>\nConstant Therapeutics LLC\n<\/li>\n<li>\nCRISPR Therapeutics AG\n<\/li>\n<li>\nCumberland Pharmaceuticals Inc\n<\/li>\n<li>\nDaiichi Sankyo Co Ltd\n<\/li>\n<li>\nDepYmed Inc\n<\/li>\n<li>\nDMD Therapeutics Inc\n<\/li>\n<li>\nDTx Pharma Inc\n<\/li>\n<li>\nDyne Therapeutics Inc\n<\/li>\n<li>\nDystrogen Therapeutics SA\n<\/li>\n<li>\nEdgewise Therapeutics Inc\n<\/li>\n<li>\nEditas Medicine Inc\n<\/li>\n<li>\nEli Lilly and Co\n<\/li>\n<li>\nEloxx Pharmaceuticals Inc\n<\/li>\n<li>\nEncell Co Ltd\n<\/li>\n<li>\nEntrada Therapeutics Inc\n<\/li>\n<li>\nEpirium Bio Inc\n<\/li>\n<li>\nEryDel SpA\n<\/li>\n<li>\nEvox Therapeutics Ltd\n<\/li>\n<li>\nFibroGen Inc\n<\/li>\n<li>\nFibroGenesis LLC\n<\/li>\n<li>\nFulcrum Therapeutics Inc\n<\/li>\n<li>\nInnoBioscience LLC\n<\/li>\n<li>\nItalfarmaco SpA\n<\/li>\n<li>\nIxchel Pharma LLC\n<\/li>\n<li>\nJ2H Biotech\n<\/li>\n<li>\nKeros Therapeutics Inc\n<\/li>\n<li>\nKSbitugen Co Ltd\n<\/li>\n<li>\nLambdaGen Therapeutics\n<\/li>\n<li>\nLudi Therapeutics\n<\/li>\n<li>\nMilo Biotechnology LLC\n<\/li>\n<li>\nMitobridge Inc\n<\/li>\n<li>\nMitochon Pharmaceuticals Inc\n<\/li>\n<li>\nMitoRx Therapeutics Ltd\n<\/li>\n<li>\nMyoGene Bio LLC\n<\/li>\n<li>\nMyos Inc\n<\/li>\n<li>\nMyosana Therapeutics Inc\n<\/li>\n<li>\nMyoTherix Inc\n<\/li>\n<li>\nNippon Shinyaku Co Ltd\n<\/li>\n<li>\nNS Pharma Inc\n<\/li>\n<li>\nOliPass Corporation\n<\/li>\n<li>\nOMEICOS Therapeutics GmbH\n<\/li>\n<li>\nOncocross Co Ltd\n<\/li>\n<li>\nOncotelic Inc\n<\/li>\n<li>\nPepgen Ltd\n<\/li>\n<li>\nPeptiDream Inc\n<\/li>\n<li>\nPfizer Inc\n<\/li>\n<li>\nPharmaxis Ltd\n<\/li>\n<li>\nPhaseBio Pharmaceuticals Inc\n<\/li>\n<li>\nPliant Therapeutics Inc\n<\/li>\n<li>\nProgenitor Therapeutics Ltd\n<\/li>\n<li>\nProthelia Inc\n<\/li>\n<li>\nPTC Therapeutics Inc\n<\/li>\n<li>\nPYC Therapeutics Ltd\n<\/li>\n<li>\nRASRx LLC\n<\/li>\n<li>\nRegenxBio Inc\n<\/li>\n<li>\nReoStem LLC\n<\/li>\n<li>\nRidgeline Therapeutics LLC\n<\/li>\n<li>\nSanthera Pharmaceuticals Holding AG\n<\/li>\n<li>\nSarcomed AB\n<\/li>\n<li>\nSarepta Therapeutics Inc\n<\/li>\n<li>\nSatellos Bioscience Inc\n<\/li>\n<li>\nSolid Biosciences Inc\n<\/li>\n<li>\nStealth BioTherapeutics Corp\n<\/li>\n<li>\nSteroTherapeutics LLC\n<\/li>\n<li>\nSutura Therapeutics Ltd\n<\/li>\n<li>\nSuzhou GenAssist Therapeutics Co Ltd\n<\/li>\n<li>\nTaiho Pharmaceutical Co Ltd\n<\/li>\n<li>\nTivorsan Pharmaceuticals Inc\n<\/li>\n<li>\nTolerion Inc\n<\/li>\n<li>\nTriplex Therapeutics Inc\n<\/li>\n<li>\nUGISense AG\n<\/li>\n<li>\nUltragenyx Pharmaceutical Inc\n<\/li>\n<li>\nVandria SA\n<\/li>\n<li>\nVertex Pharmaceuticals Inc\n<\/li>\n<li>\nVita Therapeutics Inc\n<\/li>\n<li>\nWave Life Sciences Ltd\n<\/li>\n<li>\nZata Pharmaceuticals Inc\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5589949\/duchenne-muscular-dystrophy-drugs-in-development?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=ckhqnr&amp;utm_campaign=1717444+-+Duchenne+Muscular+Dystrophy+Drugs+in+Development+Report+2022%3A+Featuring+FibroGenesis%2C+RegenxBio%2C+Pfizer+and+Others&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/btisw8<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#x3a;&#112;&#x72;&#x65;&#115;&#x73;&#x40;r&#x65;&#x73;e&#x61;&#114;c&#x68;&#97;n&#x64;&#109;a&#x72;&#107;e&#x74;&#115;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#114;e&#x73;&#115;&#64;&#x72;&#101;s&#x65;&#x61;&#114;&#x63;&#x68;&#97;n&#x64;&#109;a&#x72;&#107;e&#x74;&#x73;&#46;&#x63;&#x6f;&#109;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy &#8211; Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45366","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy &#8211; Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-22T15:01:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220622005703\/en\/1494036\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-06-22T15:01:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/\"},\"wordCount\":913,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005703\\\/en\\\/1494036\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/\",\"name\":\"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005703\\\/en\\\/1494036\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-06-22T15:01:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005703\\\/en\\\/1494036\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005703\\\/en\\\/1494036\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy &#8211; Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-22T15:01:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220622005703\/en\/1494036\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others &#8211; ResearchAndMarkets.com","datePublished":"2022-06-22T15:01:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/"},"wordCount":913,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220622005703\/en\/1494036\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/","name":"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220622005703\/en\/1494036\/21\/logo.jpg","datePublished":"2022-06-22T15:01:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220622005703\/en\/1494036\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220622005703\/en\/1494036\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/duchenne-muscular-dystrophy-drugs-in-development-report-2022-featuring-fibrogenesis-regenxbio-pfizer-and-others-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45366"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45366\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}